selected publications
- First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy. British journal of haematology. 2023 Academic Article GET IT
- Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. Communications biology. 2023 Article GET IT
- A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. Communications biology. 2022 Academic Article GET IT
- Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Frontiers in oncology. 2022 Review GET IT
- Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis. Blood advances. 2022 Academic Article GET IT
-
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Blood cancer journal.
2022
Academic Article
GET IT
Times cited: 4 -
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022
Academic Article
GET IT
Times cited: 4 - Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2021 Academic Article GET IT
-
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
The American journal of surgical pathology.
2021
Academic Article
GET IT
Times cited: 8 -
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood.
2020
Academic Article
GET IT
Times cited: 128 -
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood.
2020
Academic Article
GET IT
Times cited: 41 -
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Blood advances.
2020
Academic Article
GET IT
Times cited: 13 -
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
Blood cancer discovery.
2020
Academic Article
GET IT
Times cited: 6 -
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis.
2020
GET IT
Times cited: 1 - The gift that keeps on giving: lenalidomide maintenance after second autologous stem cell transplant in multiple myeloma. Leukemia & lymphoma. 2020 Comment GET IT
-
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
Blood cancer discovery.
2020
Academic Article
GET IT
Times cited: 37 - COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. medRxiv : the preprint server for health sciences. 2020 Article GET IT
-
Kidney transplantation in AL Amyloidosis: is it time to maximize access?.
British journal of haematology.
2019
Letter
GET IT
Times cited: 11 -
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
British journal of haematology.
2019
Academic Article
GET IT
Times cited: 48 -
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
British journal of haematology.
2019
Academic Article
GET IT
Times cited: 8 -
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
British journal of haematology.
2018
Academic Article
GET IT
Times cited: 29 -
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
British journal of haematology.
2018
Academic Article
GET IT
Times cited: 30 -
Evolving strategies in the initial treatment of multiple myeloma.
Seminars in oncology.
2013
Review
GET IT
Times cited: 3 -
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.
Journal for immunotherapy of cancer.
2013
Academic Article
GET IT
Times cited: 1215 -
Lenalidomide after stem-cell transplantation for multiple myeloma.
The New England journal of medicine.
2012
Academic Article
GET IT
Times cited: 931 -
Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease.
2008
GET IT
Times cited: 13